Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-338012
Filing Date
2026-08-06
Accepted
2026-08-06 16:11:23
Documents
67
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q inab-20260630.htm   iXBRL 10-Q 2190717
2 EX-10.1 inab-ex10_1.htm EX-10.1 328225
3 EX-10.2 inab-ex10_2.htm EX-10.2 68822
4 EX-10.3 inab-ex10_3.htm EX-10.3 56202
5 EX-31.1 inab-ex31_1.htm EX-31.1 16485
6 EX-31.2 inab-ex31_2.htm EX-31.2 16532
7 EX-32.1 inab-ex32_1.htm EX-32.1 18713
8 GRAPHIC img122832063_0.jpg GRAPHIC 702259
  Complete submission text file 0001193125-26-338012.txt   10190650

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inab-20260630.xsd EX-101.SCH 1097725
71 EXTRACTED XBRL INSTANCE DOCUMENT inab-20260630_htm.xml XML 1259576
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39692 | Film No.: 261249124
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)